The TOGETHER Project - Kidney RNA-seq Validation

Kidney Transplant Rejection Clinical Trial

— TOGETHER  

Official title:

The TOGETHER Project - Transplant Organ Genomics to Help Prevent Rejection in Kidney Transplant Recipients-RNA-seq Signature Validation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03874299
• Other study ID #: 16-004433
• Status: Completed
• Start date: November 17, 2016
• Est. completion date: June 20, 2019

Study information

• Verified date: September 2022
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The researchers are trying to develop a way to measure the risk of rejection through the validation of a blood test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 302
• Est. completion date: June 20, 2019
• Est. primary completion date: June 20, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult (>/=18 years) renal transplant recipient.

• Patients who have given informed consent and are willing to comply with the protocol, including the use of their peripheral blood specimens and data for subsequent research.

Exclusion Criteria:

-Adult (<18 years) renal transplant recipient.

Related Conditions & MeSH terms

• Kidney Transplant Rejection

Locations

Country	Name	City	State
United States	Mayo Clinic	Jacksonville	Florida
United States	Mayo Clinic	Rochester	Minnesota
United States	Mayo Clinic	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To validate the use of a RNA-seq based peripheral blood assay in renal transplant recipients.	The study will validate the ability of a peripheral blood assay to assess the risk of biopsy proven rejection.	3 years

External Links

•   Mayo Clinic Clinical Trials